The Oncology Research Internship (ORI) is a unique opportunity for participants to learn about oncology research from our team of Oncology Research Professionals.

Five (5) Oncology Research Interns will be selected from applications received. Limiting Internship to five candidates will provide a learning experience that is up-close and personal.

WHO CAN APPLY?
1) High School Seniors: Class of 2018 or 2019
2) First year college students who would like to obtain basic knowledge about cancer, cancer treatment and the research process are welcome to apply.

WHAT ARE THE DATES FOR THE INTERNSHIP? ORI will begin on June 18 and will end on July 13 (4 weeks in length). An average day during the ORI will be 5–8 hours in length.

PROGRAM REQUIREMENTS
♦ Parental / Guardian Permission
♦ Good academic standing & Satisfactory conduct/grades
♦ Proof of medical insurance coverage
♦ A video submission or written essay explaining why the applicant would like to be an Oncology Research Intern participant
♦ Letter of Recommendation from a previous teacher
♦ Students are responsible for transportation to and from UT Health Cancer Center
♦ Out of town candidates are responsible for housing

For more information please contact:
Rachel Ortiz-Wong, Project Coordinator
UT Health Cancer Center – Institute for Drug Development
Phone: (210) 450-5055
For security and safety reasons it is the University’s decision that visiting individuals establish legitimacy on campus and receives all necessary training and testing to assure their own and the University’s patients safety. Thus, the program has a new protocol for participation.

Confidentiality /Security Acknowledgment

APPLICATION PROCESS
Application form will be provided for completion. There is a step I, II & III process where applicable. There is a $25.00 processing fee. A background check form will need to be completed.

OTHER FEES
Obtaining University Badge ($10 charge)
Parking Permit (cost of parking permit varies based on location)

Application Deadline
March 2, 2018

Institute for Drug Development®

Seeking Cures & Patients for Phase I, II & III Clinical Trials

UT Health Cancer Center’s Institute for Drug Development (IDD®), pushes the frontier of cancer research to develop novel cancer treatments through partnerships with the NCI and with pharmaceutical and biotechnology companies. The IDD® accelerates the development of anticancer agents by integrating basic, translational and clinical research on the UT Health San Antonio campus with Cancer Center clinicians. Many hundreds of anticancer agents have been tested here and many of the most important and effective cancer drugs currently in use today were either developed or first tested at IDD®.

Patients receive the standard of care and they have access to the latest treatments available. Cancer Center faculty specialize in different tumor types and use their expertise to choose the best option for each patient.

Each year, more than 350 patients from around the world come to UT Health Cancer Center to participate in clinical trials and receive treatment with new drugs. At any given time, the Cancer Center is testing as many as 60 new drugs.

The IDD® is home to one of the world’s largest Phase I clinical studies programs for evaluating new cancer drugs. Phase I clinical studies are the first time that a new compound is used in patients, the initial step toward approval from the Food & Drug Administration. These studies establish the safety and appropriate dosage of new cancer drugs. The Cancer Center also conducts Phase II and Phase III trials which continue to evaluate a drug’s safety, effectiveness and to compare it with current standard of care.

The IDD® is funded by grants from the NCI and the Department of Defense, other public agencies and private foundations, industry contracts, clinical practice, philanthropy and investments.

Program Coordinators

S. Lisa Creighton, BS, CCRP
Regulatory Affairs Manager
210-450-1366 | creighton@uthscsa.edu

Rachel Ortiz-Wong
Project Coordinator
210-450-5055 | wongro@uthscsa.edu

For more information please contact:

Rachel Ortiz-Wong, Project Coordinator
UT Health Cancer Center
Institute for Drug Development
Phone: (210) 450-5055